Introduction
The cyclic nucleotides cAMP and cGMP are utilized in a wide variety of signaling pathways. They are synthesized by adenylyl and guanylyl cyclases, and hydrolyzed to the corresponding 5 0 -monophosphates by 3 0 ,5 0 -cyclic nucleotide phosphodiesterases (PDEs). There are 21 human PDE genes divided into 11 families based on their protein sequence, affinity for cAMP and cGMP, regulation, and sensitivity to inhibitors. 1 Alternative splicing of PDE mRNAs occurs at the 5 0 -and/or 3 0 -ends of the transcripts for most of the 21 genes, which yields at least 80 different PDE proteins.
The PDE11 family is the most recently described PDE family. [2] [3] [4] It contains one gene, PDE11A. Four splice variants have been described, which encode four proteins. [2] [3] [4] All four PDE11A proteins contain the same catalytic region; however, the length and/ or composition of their amino termini differ. PDE11A3 (78 kDa) and PDE11A4 (105 kDa) differ at their amino termini. PDE11A1 (56 kDa) and PDE11A2 (66 kDa) are amino-truncated versions of PDE11A3/PDE11A4; their amino-acid sequences are completely contained within the common region of the longer forms.
Since it has been so recently discovered, the physiological role of PDE11A has not been determined. Tadalafil (Cialis s ), a PDE5A inhibitor used for the treatment of male erectile dysfunction, has been reported to partially inhibit PDE11A. 5, 6 It was therefore of interest to consider the pattern of expression of this enzyme in human tissues. However, the literature contains conflicting reports on this subject. [2] [3] [4] [7] [8] [9] [10] [11] [12] In this study, we sought to clarify our understanding of PDE11A expression in a panel of human tissues. We used antibodies to PDE11A in Western blots to examine the expression of PDE11A protein forms in human prostate, pituitary, testis, heart, penis, skeletal muscle, and liver samples. We also studied the localization of PDE11A within heart and prostate by immunohistochemistry.
Materials and methods

Human tissue samples
The human tissue extracts used for the Western blots shown in Figure 1 were purchased (BD Biosciences/ Clontech, Palo Alto, CA, USA for skeletal muscle, liver, heart; BioChain, Hayward, CA, USA for pituitary, testis, penis) or prepared (see below) from OCT-embedded frozen tissue (National Disease Research Interchange (NDRI), Philadelphia, PA, USA for prostate). Six extracts were obtained from single donors (prostate (male, age 28 y), pituitary (male, age 71 y), testis (male, age 26 y), liver (female, age 37 y), heart (male, age 44 y), penis (male, age 32 y)) and one sample was pooled from three donors (skeletal muscle (male, ages 30-47 y)). Additional human tissue samples used for Western blots were purchased (BD Biosciences/Clontech, Palo Alto, CA, USA for testis (pool of 18 men, ages 19-64 y); BioChain, Hayward, CA, USA for prostate (male, age 69 y), heart (male, age 26 y), skeletal muscle (male, age 26 y), liver (male, age 24 y)) or were prepared from frozen tissue (heart (male, age 33 y), testis (male, age 18 y), skeletal muscle (female, age 13 y), penis (male, this sample was obtained from the Department of Urology at the University of Washington, Seattle, WA, USA) or from OCT-embedded frozen tissue (prostate (male, age 65 y; this sample was obtained from Harborview Hospital, Seattle, WA, USA), pituitary (male, age 59 y), testis (male, age 28 y)). Snap-frozen tissue samples were pulverized under liquid nitrogen and OCT-embedded frozen tissue samples were sectioned using a model CM1900 Leica cryostat (Bannockburn, IL, USA) prior to detergent-solubilization. 13 Protein integrity was monitored by Coomassie staining following polyacrylamide gel electrophoresis.
Tissue for immunohistochemistry was obtained from NDRI. Prostate (male, age 28 y) and heart (male, age 41 y) samples are shown in Figures 2 and 3 , respectively. Additional prostate samples (male, age 65 y; male, age 46 y) and heart samples (male, age 30 y; male, age 14 y; male, age 23 y; male, age 31 y; and female, age 38 y) were also studied.
Expression of recombinant PDE11A proteins
Full-length PDE11A1 was obtained by reverse transcription followed by polymerase chain reaction (RT-PCR) using skeletal muscle cDNA (first-strand cDNA synthesis kit for RT-PCR (AMV), Roche Diagnostics Corp, Indianapolis, IN, USA). Additional PDE11A2 and PDE11A4 sequences were obtained by RT-PCR from prostate cDNA; PDE11A3 sequences were obtained from testis cDNA (BD Biosciences/Clontech, Palo Alto, CA, USA). PDE11A1 and PDE11A4 were cloned into the pSG5 mammalian expression vector (Stratagene, La Jolla, CA, USA) and transfected into Cos-7 cells using a chloroquine-DEAE Dextran method.
14 PDE11A2 and PDE11A3 were produced in Sf9 insect cells using the Bac-to-Bac s expression system (Invitrogen, Carlsbad, CA, USA). Extracts containing the recombinant PDE11A proteins were used as size standards on the Western blots ( Figure 1) ; the migration of the recombinant proteins is consistent with their predicted molecular weights.
PDE11A1 with an amino-terminal 10 Â His tag was also expressed in Sf9 cells and partially purified using a nickel column (Qiagen, Valencia, CA, USA) (Mike Gadau, personal communication). 5 We determined the protein concentration of the partially purified PDE11A1 and used this material in Western blots to estimate the sensitivity of antibody 417L (see below).
PDE11A-selective antibodies
The carboxy-terminal 87 amino acids of PDE11A were expressed in Escherichia coli as a GST-fusion protein using pGEX-5X-1 (Amersham Biosciences, Piscataway, NJ, USA) and gel purified. Mouse monoclonal antibodies were generated using standard procedures. 15 Antibody epitopes were mapped using a deletion series (Erase-a-Base s kit, Promega, Madison, WI, USA) and peptides (PD11-111P, FabGennix, Shreveport, LA, USA and a custom peptide from Genemed Synthesis, South San Francisco, CA, USA). Antibody 479F (epitope within amino acids 410-424 of PDE11A1, SAIFDRNRKDELPRL) and antibody 417L (epitope within amino acids 454-467 of PDE11A1, VATNRSKWEELHQK) both recognize all four recombinant PDE11A forms ( Figure 1 ). Neither antibody detected recombinant PDE1-5 or PDE7-10 proteins by Western analysis (data not shown). Crossreactivity to PDE6 was not determined.
Western analysis
For purchased tissue extracts, 15 mg was loaded per gel lane. Based on Coomassie staining, a similar amount of prostate sample was used. Samples were electrophoresed in 10% polyacrylamide gels (NOVEXt, Invitrogen, Carlsbad, CA, USA) with a buffer containing 25 mM Tris, 192 mM glycine, 0.1% SDS, and transferred to Immobilont-P membrane (Millipore Corp., Bedford, MA, USA) for Western blot analysis. 15 Antibodies were applied in blocking solution (100 mM NaCl, 20 mM Tris-HCl pH 7.5, 5% Carnation s nonfat powdered milk, 0.1% Tween-20). The secondary antibody was a horseradish peroxidase-conjugated, AffiniPuret donkey anti- 
Results
Western blots using human tissue extracts
We used two PDE11A antibodies for Western blot analyses to determine which PDE11A protein form(s) were present in human prostate, pituitary, skeletal muscle, testis, liver, heart, and penis samples.
Recombinant PDE11A1, PDE11A2, PDE11A3, and PDE11A4 were run as size standards. Using antibody 417L (Figure 1a) , an immunoreactive band consistent in size with PDE11A4 (105 kDa) was detected in the prostate and pituitary samples. A faint PDE11A4-sized band was also present in the liver and heart samples. The remaining faint bands appeared to be due either to degradation of the PDE11A4 bands or to proteins crossreacting with the secondary antibody (Figure 1c ). PDE11A-specific immunoreactive bands were not detected in the testis, penis, or skeletal muscle samples with the 417L antibody. The Western blots were repeated using samples from additional individual donors (two prostate, one pituitary, two skeletal muscle, two testis, one heart, one penis) and pooled donors (testis (18 men)) ; the results were similar to those shown in Figure 1a . In contrast, PDE11A-specific immunoreactive bands were not detected in an additional heart sample and an additional liver sample (data not shown).
The 105 kDa immunoreactive band observed with antibody 417L (Figure 1a ) migrated with the same mobility as recombinant PDE11A4. However, we wished to confirm its identity by using a second PDE11A antibody that recognized a different region of the PDE11A proteins. Using antibody 479F (Figure 1b) , PDE11A4-sized bands were again detected in prostate, pituitary, liver, and heart samples. Antibody 479F also recognized a very large protein (B175 kDa) in skeletal muscle and heart, which we believe to be unrelated to PDE11A (see Discussion). PDE11A-sized immunoreactive bands were not detected in the testis, penis, or skeletal muscle samples with antibody 479F (Figure 1b) .
Immunohistochemistry on human tissues
To localize PDE11A within prostate and heart, we performed immunohistochemistry using antibody 417L on human tissue sections. In the prostate, the glandular epithelium showed dark immunostaining while the basal epithelial layer was not stained (Figure 2 ). The faint staining in the stromal smooth PDE11A: localization in human tissues K Loughney et al muscle was similar in intensity to that noted for the controls. Prostate samples from two additional donors showed similar immunostaining (data not shown). In the heart, there was no detectable staining in the cardiac myocytes or blood vessels (Figure 3a) . However, there was light staining of the neuronal cell bodies within a parasympathetic ganglion (Figure 3b ). We examined heart samples from five additional donors, one of which also contained a parasympathetic ganglion (data not shown). The pattern of immunostaining was identical to the sample shown here, except that in some samples a small subset of nerves also showed very light immunostaining.
Discussion
Our results demonstrated the presence of PDE11A4 protein in human prostate, pituitary, heart, and liver. This was the only form of PDE11A protein detected in these samples. Within the prostate, PDE11A was found in the glandular epithelium. In heart, PDE11A was not detected in the cardiac myocytes or blood vessels. Low levels of PDE11A were detected in neuronal cell bodies within cardiac parasympathetic ganglia and in a subset of nerves. PDE11A protein was not detected in human skeletal muscle, testis, or penis. Our PDE11A protein localization results are partially consistent with the published reports on the distribution of PDE11A mRNA. [2] [3] [4] 7 However, our results differ substantially from the published reports on the distribution of PDE11A protein. 2, [8] [9] [10] [11] [12] We believe this could be due to differences in the specificity and selectivity of the PDE11A antibodies used for the PDE11A protein localization work.
We detected PDE11A4 protein in prostate, pituitary, heart, and liver, in agreement with published analyses of PDE11A mRNA using Northern blots, dot blots, and RT-PCR. 2, 4, 7 Published reports also indicate the presence of PDE11A1 mRNA in skeletal muscle, as well as low levels in prostate and liver. 2, 7 PDE11A3 mRNA has been reported in testis.
3,4,7 We did not detect PDE11A1 or PDE11A3 protein in any of these tissues by immunoblotting (Figure 1 ). This could reflect low protein levels, instability of the PDE11A protein, variation between donors, or variation between anatomical sites of sample collection. To address some of these possibilities, we examined tissue from several additional donors and did not detect PDE11A1 or PDE11A3 protein in any sample.
For testis, another possible explanation for the presence of PDE11A3 mRNA but the absence of PDE11A3 protein is suggested by the genomic structure of PDE11A3. In mice and rats, transcription of PDE11A3 uses the promoter of the testisspecific cytochrome-c gene, which is expressed only in spermatocytes and spermatids. 16, 17 In humans, this gene is a nonfunctional pseudogene (HCP9). 7, 18 The initiation methionine for the PDE11A3 protein is within the protein-coding region for cytochrome-c but is in a different reading frame. Given this unusual structure, it seems important to establish that the PDE11A3 mRNA is actually translated to give a PDE11A3 protein in these different species.
Although our results agree, in part, with published reports on the distribution of PDE11A mRNA, they differ substantially from the reported distribution of PDE11A protein. 2, [8] [9] [10] [11] [12] For example, in prostate tissue, we detected only PDE11A4 protein, whereas other investigators found only PDE11A1 protein.
2
PDE11A has been reported in both epithelial and subepithelial layers of the prostatic glands; however, we detected it only in the epithelial layer. 11, 12 In addition, we did not detect any PDE11A protein in skeletal muscle. This contrasts with a report of PDE11A3 as the major protein form in skeletal muscle, with minor amounts of PDE11A1 and PDE11A2 also present. 
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Furthermore, we do not detect any PDE11A protein in testis. This disagrees with the report of PDE11A protein in spermatogonia, spermatocytes, spermatids, Leydig cells, and the vascular smooth muscle of the testis. 8 Although we did detect PDE11A4 in heart, it was present in low levels in the parasympathetic neuronal cell bodies but not in cardiac myocytes or vasculature. This disagrees with a report of PDE11A protein found in atrial and ventricular myocytes as well as the vascular smooth muscle. 9 Finally, we did not detect any form of PDE11A protein in the penis, in contrast to the report of PDE11A protein in the corpus cavernosal and vascular smooth muscle of the penis. 10 Our observation that PDE11A4 protein appears to be present in the pituitary agrees with published results. 8 However, we have not determined which cell types within the pituitary contain PDE11A4.
The differences outlined above may reflect the specificity and sensitivity of the antibodies used for the analyses. Antibody 417L detected less than 1 ng of partially purified PDE11A1 protein. In our Western blots using antibody 417L, the only bands detected were the same size as recombinant PDE11A proteins run as size standards. The absence of these bands in control blots, which were incubated with only the secondary antibody, confirmed that the bands were specifically recognized by antibody 417L. Additionally, the bands comigrated with recombinant PDE11A proteins, supporting that they were PDE11A proteins. We also used a second antibody, 479F, which recognized a different region of the PDE11A proteins. In Western blots, it recognized bands of the same size as were seen with antibody 417L, confirming their identity as PDE11A proteins. Antibody 479F also recognized a B175 kDa protein in heart and skeletal muscle. We believe this large immunoreactive band is unrelated to PDE11A for three reasons. First, the B175 kDa protein was not detected by antibody 417L (Figure 1a) . Secondly, two additional antibodies to PDE11A did not detect immunoreactive bands of this size. One antibody was specific for an epitope near the amino terminus of PDE11A1, the second recognized the same region of PDE11A1 as did antibody 479F (data not shown). Thirdly, no B175 kDa PDE11A forms have been described. [2] [3] [4] The literature includes a Western blot of PDE11A in skeletal muscle and a large protein of this size was not observed. 2 It should also be noted that it is not uncommon for monoclonal antibodies to recognize several different proteins. 19 Most of the published work used a polyclonal antipeptide antibody, EPH-3, which recognized an epitope within the same 15 amino-acid region of the PDE11A proteins recognized by antibody 479F. 2, [8] [9] [10] A second antibody described in the literature recognized the same region as does our 417L antibody. 2 The absence of recombinant standards for all four PDE11A proteins in the published studies makes it difficult to verify that the proteins detected by these antibodies are, in fact, PDE11A proteins. 2 One possible explanation for the differences between our localization results and the published work is that the antibodies described in the literature recognize proteins in addition to PDE11A, which are widely distributed in human tissues, and which are confounding the interpretation of Western and immunohistochemical localization analyses. 2, [8] [9] [10] [11] [12] The function of PDE11A, which hydrolyzes both cAMP and cGMP, in the glandular epithelium of the prostate and in the neuronal cell bodies within parasympathetic ganglia of the heart is unknown. In prostate, the glandular epithelium lines the prostatic ducts and secretes prostatic fluid, which contains a number of different substances making up 20-30% of semen volume. In heart, parasympathetic neurons release acetylcholine, which slows the heart rate. We also detect PDE11A in a subset of nerves within the heart but we do not know if this reflects selective immunostaining of parasympathetic nerve axons or staining of other kinds of axons as well. Specific roles for PDE11A in the heart and prostate will have to be defined using selective inhibitors.
No PDE11A-selective inhibitors have been reported, however, there has been interest in PDE11A inhibition by tadalafil. We have previously reported that tadalafil is 14-fold selective for inhibition of PDE5A compared to PDE11A1, while others have reported five-fold selectivity. 5, 6 In a recent study of recombinant PDE11A4, tadalafil showed an IC 50 value of 73 nM and had 40-fold selectivity for inhibition of PDE5A compared to PDE11A4. 20 Thus, PDE11A4 appeared less sensitive to inhibition by tadalafil than did PDE11A1. This agreed with results indicating that PDE11A4 was less sensitive than a shorter form (PDE11A3) to a panel of inhibitors. The authors of that report cited a number of examples where the amino-terminal portion of a PDE protein influenced its sensitivity to inhibitors. 4 In this regard, it should be noted that the clinical experience with tadalafil has not revealed any effects that can be ascribed to inhibition of PDE11A. The side effects that have been observed are consistent with those expected from inhibition of PDE5A. 21, 22 Therefore, determining the physiological role(s) of PDE11A will require the identification of potent and selective inhibitors.
